P. Legmann (Professeur des Universités, praticien hospitalier, chef de service), O. Vignaux (Professeur des Universités, praticien hospitalier), J. Uzan-Augui (Praticien hospitalier), H. Gouya (Chef de clinique-assistant des Hôpitaux), S. Silvera (Chef de clinique-assistant des Hôpitaux), A.-E. Millischer-Bellaiche (Chef de clinique-assistant des Hôpitaux), H. Bahurel-Barrera (Praticien attaché)
{"title":"经皮肝内口系统吻合","authors":"P. Legmann (Professeur des Universités, praticien hospitalier, chef de service), O. Vignaux (Professeur des Universités, praticien hospitalier), J. Uzan-Augui (Praticien hospitalier), H. Gouya (Chef de clinique-assistant des Hôpitaux), S. Silvera (Chef de clinique-assistant des Hôpitaux), A.-E. Millischer-Bellaiche (Chef de clinique-assistant des Hôpitaux), H. Bahurel-Barrera (Praticien attaché)","doi":"10.1016/j.emcrad.2005.01.002","DOIUrl":null,"url":null,"abstract":"<div><p>Transjugular intrahepatic porto-systemic shunts (TIPS) have been developed in the 80’s, for the treatment of portal hypertension complications. Their indications include active bleeding from gastro-esophageal varix, and control of refractory cirrhotic ascites, especially in patients awaiting liver transplantation. New indications include hepatic hydrothorax, hepato-renal failure, and the treatment of the Budd-Chiari syndrome. TIPS have been shown to provide better control than endoscopic sclerotherapy, in the prevention of re-bleeding from gastro-esophageal varix and in the treatment of refractory cirrhotic ascites. Complications of TIPS procedures are possible and include encephalopathy, stent occlusion and stenosis. Using Polythetrafluoroethylen covered endoprosthesis (EPTFE) should improve the permeability of the TIPS.</p></div>","PeriodicalId":100447,"journal":{"name":"EMC - Radiologie","volume":"2 2","pages":"Pages 183-196"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emcrad.2005.01.002","citationCount":"0","resultStr":"{\"title\":\"Anastomose portosystémique intrahépatique percutanée\",\"authors\":\"P. Legmann (Professeur des Universités, praticien hospitalier, chef de service), O. Vignaux (Professeur des Universités, praticien hospitalier), J. Uzan-Augui (Praticien hospitalier), H. Gouya (Chef de clinique-assistant des Hôpitaux), S. Silvera (Chef de clinique-assistant des Hôpitaux), A.-E. Millischer-Bellaiche (Chef de clinique-assistant des Hôpitaux), H. Bahurel-Barrera (Praticien attaché)\",\"doi\":\"10.1016/j.emcrad.2005.01.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Transjugular intrahepatic porto-systemic shunts (TIPS) have been developed in the 80’s, for the treatment of portal hypertension complications. Their indications include active bleeding from gastro-esophageal varix, and control of refractory cirrhotic ascites, especially in patients awaiting liver transplantation. New indications include hepatic hydrothorax, hepato-renal failure, and the treatment of the Budd-Chiari syndrome. TIPS have been shown to provide better control than endoscopic sclerotherapy, in the prevention of re-bleeding from gastro-esophageal varix and in the treatment of refractory cirrhotic ascites. Complications of TIPS procedures are possible and include encephalopathy, stent occlusion and stenosis. Using Polythetrafluoroethylen covered endoprosthesis (EPTFE) should improve the permeability of the TIPS.</p></div>\",\"PeriodicalId\":100447,\"journal\":{\"name\":\"EMC - Radiologie\",\"volume\":\"2 2\",\"pages\":\"Pages 183-196\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.emcrad.2005.01.002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMC - Radiologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1762418505000038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Radiologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1762418505000038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Transjugular intrahepatic porto-systemic shunts (TIPS) have been developed in the 80’s, for the treatment of portal hypertension complications. Their indications include active bleeding from gastro-esophageal varix, and control of refractory cirrhotic ascites, especially in patients awaiting liver transplantation. New indications include hepatic hydrothorax, hepato-renal failure, and the treatment of the Budd-Chiari syndrome. TIPS have been shown to provide better control than endoscopic sclerotherapy, in the prevention of re-bleeding from gastro-esophageal varix and in the treatment of refractory cirrhotic ascites. Complications of TIPS procedures are possible and include encephalopathy, stent occlusion and stenosis. Using Polythetrafluoroethylen covered endoprosthesis (EPTFE) should improve the permeability of the TIPS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
